IGF-I and diabetes in adolescence

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pediatric Endocrinology

Background:

• Adolescents with insulin-dependent diabetes mellitus (IDDM) often face challenges in achieving optimal glycemic control.
• Intensified insulin therapy can lead to hypoglycemia and weight gain, while GH/IGF-I axis abnormalities contribute to poor control.
• Reduced insulin-like growth factor-I (IGF-I) levels and bioactivity, despite growth hormone (GH) hypersecretion, are common in IDDM adolescents.

Purpose of the Study:

• To evaluate the efficacy and safety of recombinant human IGF-I (rhIGF-I) as an adjunct to insulin therapy in adolescents with IDDM.
• To investigate the impact of rhIGF-I on glycemic control, GH/IGF-I axis, and insulin sensitivity.
• To assess potential adverse effects and diabetic complications associated with rhIGF-I treatment.

Main Methods:

• Conducted randomized placebo-controlled clinical trials involving daily subcutaneous administration of rhIGF-I (40-80 micrograms/kg/day) to adolescents with IDDM.
• Monitored glycemic control through HbA1c levels, assessed GH and IGF-I levels, and evaluated insulin sensitivity.
• Tracked for adverse events, including hypoglycemia, weight gain, and exacerbation of diabetic complications.

Main Results:

• rhIGF-I therapy significantly reduced HbA1c levels compared to placebo.
• Circulating IGF-I levels were restored, leading to suppressed GH levels and improved insulin sensitivity.
• No evidence of toxicity or exacerbation of diabetic complications was observed during the trials.

Conclusions:

• rhIGF-I, when used as an adjunct to insulin therapy, offers a potential new approach for managing IDDM in adolescents.
• This therapy can improve glycemic control and address GH/IGF-I axis abnormalities.
• Further research is needed to determine optimal dosing and confirm long-term safety, particularly regarding microvascular complications.